Tekedia Capital congratulates our portfolio company, Revna Biosciences, for a groundbreaking collaboration between AstraZeneca, a global biopharmaceutical company, and the sub-Saharan African leader in precision medicine and advanced diagnostics. This strategic partnership will deepen Epidermal Growth Factor Receptor (EGFR) biomarker testing in Africa, significantly enhancing early diagnosis and personalized treatment for patients with non-small cell lung cancer (NSCLC).
EGFR is a protein that plays a crucial role in cell growth and division. Mutations in the EGFR gene can cause cancer cells—particularly in NSCLC—to grow more rapidly. Testing for EGFR mutations helps physicians determine the best course of treatment, including targeted therapies that offer better outcomes with fewer side effects than traditional chemotherapy.
Tekedia Capital continues to fund the future of Africa by investing in innovative startups which are fixing frictions in the Africa market. To the Revnabio Team, well done!
Register for Tekedia Mini-MBA edition 19 (Feb 9 – May 2, 2026): big discounts for early bird.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment (next edition begins Jan 24 2026).
---
Connect via my
LinkedIn |
Facebook |
X |
TikTok |
Instagram |
YouTube